PipelineReview.com13h
Viking Therapeutics Announces Initiation of Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity
Study to Evaluate the Safety and Efficacy of Oral VK2735 Dosed Once Daily. SAN DIEGO, CA, USA I January 8, 2025 I Viking Therapeutics, Inc. (“Viking”) (NASDAQ: VKTX), ...
PipelineReview.com13h
Bitterroot Bio Reports Data on Safety and Target Engagement from Phase 1 First-in-Human Study of BRB-002 in Healthy Volunteers
PALO ALTO, CA and NEEDHAM, MA, USA and MELBOURNE, Australia I January 08, 2025 I Bitterroot Bio, a leader in developing innovative medicines in the field of ...
PipelineReview.com21h
Metsera Announces Positive Topline Phase 2a Clinical Data for its Ultra-Long Acting GLP-1 Receptor Agonist, MET-097i
NEW YORK, NY, USA I January 07, 2025 I Metsera, Inc., a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases, today announced ...
PipelineReview.com21h
Citius Pharmaceuticals and Citius Oncology Highlight LYMPHIR Commercial Launch Planned for the First Half of 2025
CRANFORD, NJ, USA I January 7, 2025 I Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR) and its oncology-focused subsidiary, ...
PipelineReview.com22h
Variant Bio Announces Multi-Year Research Partnership with Novo Nordisk to Discover Novel Targets for Metabolic Disease
SEATTLE, WA, USA I January 7, 2025 I Variant Bio, a genomics-driven drug discovery company, today announced a multi-year research collaboration with Novo ...
PipelineReview.com21h
XyloCor Therapeutics Raises $67.5 Million in Series B Financing to Advance Clinical Development of Novel Gene Therapy in Cardiovascular Disease
New investor Jeito Capital, a global leading private equity fund, led the Series B financing round which also included existing institutional investors EQT, Fountain Healthcare Partners, and Lumira ...
PipelineReview.com21h
Avenzo Therapeutics and DualityBio Announce Exclusive Global License for Potential Best-In-Class EGFR/HER3 Antibody-Drug Conjugate
Avenzo to receive exclusive global license (excluding Greater China) for development, manufacturing and commercialization of potential best-in-class EGFR/HER3 ...
PipelineReview.com1d
I-Mab Announces Portfolio Prioritization of Givastomig (CLDN18.2 x 4-1BB Bispecific Antibody) as Lead Clinical Program
ROCKVILLE, MD, USA I January 6, 2025 I I-Mab (NASDAQ: IMAB) (the "Company"), a U.S.-based, global biotech company, focused on the development of precision ...
PipelineReview.com1d
Denali Therapeutics Announces Topline Results for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial
SOUTH SAN FRANCISCO, CA, USA I January 06, 2025 I Denali Therapeutics Inc. (NASDAQ: DNLI) today announced topline results from an analysis of Regimen G of the ...
PipelineReview.com1d
GlycoNex Announces Licensing Agreement for SPD8 Biosimilar
Under the terms of the agreement, the licensee will obtain rights to develop, secure regulatory approval for, and commercialize SPD8 in the designated market. The licensing agreement includes ...
PipelineReview.com1d
Candid Therapeutics Enters into Agreement with WuXi Biologics on Trispecific T-cell Engager
SAN DIEGO, CA, USA & SHANGHAI, China I January 06, 2024 I Candid Therapeutics, Inc. (“Candid”), a clinical-stage biotechnology company focused on becoming ...
PipelineReview.com5d
Hanx Biopharmaceuticals, Ltd. Announces First Patient Dosing in First-in-Human Phase 1 Clinical Trial of HX044
WUHAN, China I, 2025 I Hanx Biopharmaceuticals, CO. Ltd, an innovative biotechnology company developing next-generation immunotherapies to address ...